

H I G H L I G H T S

CONTACTS & KEY INFORMATION

Headquarters	3 rue de Verdun-Bat G 78590 Noisy le Roi, France Tel: +33 161 06 19 92 Fax: +33 130 56 50 35
Website	www.art-stent.com
Employees	4
Sector	Cardiovascular stenting
Financing	Sept. 2007, Series "B"
Core Technology	Bioresorbable stents that facilitate the body's natural arterial remodeling process
Contact	Ronald C. Trahan, APR Ronald Trahan Associates, Inc. (508) 359-4005, x108

BOARD OF DIRECTORS

Machiel van der Leest, CEO, ART

On Nov. 4, 2008, ART announced that it appointed Machiel van der Leest as its Chief Executive Officer. Most recently, van der Leest was ART's Chief Operating Officer since March 2008. Prior to joining ART, he was Director of R&D and Regulatory Affairs since May 2003 at Minvasys.

Eric Viaud, MS (Chairman)

Co-founder, Chairman and CEO of Gene Signal, Eric Viaud has spent more than 20 years in the medical and pharmaceutical industries (BASF, Synthelabo, Medtronic) working in the areas of reimbursement, development, licensing, marketing and sales in France, UK, Germany and Switzerland.

Thierry Chignon, PharmD, MBA

Dr. Chignon is Investment Manager for Matignon Technologies, principal investor in ART. He was former Consultant to the Commission of the European Union, Medical Device unit, for five years and actively participated in the development of the European regulatory framework.

Philippe Dhamelincourt

Philippe Dhamelincourt is co-founder and Vice-Chairman of Matignon Investissement & Gestion. Dhamelincourt has been involved in French capital investment activities for nearly 40 years.

▶ **Arterial Remodeling Technologies ("ART") is developing *bioresorbable peripheral and coronary polymer stents* that promote the natural remodeling of an injured artery after angioplasty.** The Company's technology is based on intellectual property originating from three esteemed institutions: the **Cleveland Clinic**; the French national research institute, **C.N.R.S.** (Centre National de Recherche Scientifique), Montpellier, France; and, **Descartes University**, Paris. ART has raised €6.5 million (\$9.75 million) from VCs **Matignon Technologies** and **SGAM Alternative Investments**.

▶ **ART's bioresorbable stents are designed to dismantle *in vivo* over an *optimized time horizon*, thus allowing the body's own natural arterial remodeling process to occur, unrestricted by the presence of a permanent metallic stent.** The Company's proprietary, polymer-based technology promotes the natural remodeling of an injured and/or diseased artery after angioplasty or other similar procedures. ART has established proof-of-concept with preclinical implantation studies in iliac and coronary models that can be applied and adapted to a wide variety of stent designs.

▶ **ART's platform benefits from Pr. Michel Vert's 30 years of trade secret savoir-faire in biodegradable polymers.** The Company's innovative stents consist of proprietary polymers that are non-inflammatory, biocompatible, hemocompatible, mechanically strong and biodegradable. These novel polymers are developed in conjunction with one of the world's leading authorities in polymer chemistry, Professor Michel Vert, who is Former Director of the Research Center for Artificial Biopolymers at France's National Center for Scientific Research (Centre National de Recherche Scientifique/C.N.R.S.).

▶ **Application of ART's novel polymer technology to the development of its bioresorbable stents gives them several distinct advantages over permanent stents.** The next-generation-approach being pursued by ART is to achieve *temporary* stenting of a traumatized angioplasty site, for example, to (a) prevent acute and chronic recoil; (b) allow the arterial wall to remodel through the use of a stent that dismantles; and (c) allow natural physiological healing and remodeling processes to proceed.

▶ **ART is led by CEO Machiel van der Leest, of whom ART Director Dr. Thierry Chignon said upon van der Leest's election as ART's CEO:** "Given ART's approach of achieving *temporary* stenting of a traumatized angioplasty site, the Company expects to benefit greatly from Machiel's proven understanding of the development, regulatory, clinical, manufacturing and market dynamics of the stent sector."

Bioresorbable Stents Clinically Proven in 2009

(Source: *Diagnostic and Invasive Cardiology*, Sept-Oct 2009 Issue, "Dissolving Stents May Offer New Options in the Next Decade) Two-year data...from the 30-patient, first-in-man ABSORB trial using the (Abbott Vascular) BVS (Biodegradable Vascular Solutions stent) were...published in *The Lancet* in March (2009). There were no cases of thrombosis and no new major adverse cardiac events (MACE) between six months and two years...The data seems to show the stent may offer a **new standard of care in coronary artery disease**, said **John Ormiston, M.D.**, a principal investigator in the ABSORB trial and medical director at Mercy Angiography in Auckland, New Zealand...

"Interventional cardiology has come a long way. It started with balloon angioplasty, which evolved into bare metal stents and then drug eluting metal stents were created," said **Patrick W. Serruys, M.D., Ph.D.**, professor of interventional cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, and principal investigator of the ABSORB trial, during the launch of the second phase of the ABSORB trial. "Now we have the fourth revolution in interventional cardiology technology, and patient outcomes from the first stage of ABSORB clearly show that **bioabsorbable devices are the future of coronary artery disease treatment.**"